Solid-Tumor CAR-T — China
Current focus: CLDN18.2-positive, HER2-negative, advanced gastric or gastro-esophageal junction cancer in appropriate later-line cases. The pathway is case-specific and is not a determination of eligibility.
Records to prepare
Biomarker and pathology records, prior-line treatment history and response, recent imaging, current clinical status, current labs, and a treating-physician summary where available.
When provider input is available, Vialen can clarify review requirements and what may be known before travel. Treating centres retain independent clinical judgment and make all treatment decisions.
Submit a Clinical Case
Cases currently relevant
CLDN18.2-positive, HER2-negative, advanced gastric or gastro-esophageal junction cancer in appropriate later-line cases. Biomarker status and later-line context alone do not determine eligibility.
How the case moves
Vialen checks record completeness and route relevance. Where a verified and available treatment-centre route exists, records may be prepared for independent clinical review. The treating centre may define additional requirements and makes its own decision; any further episode details depend on provider input.